Lifetime Medical Costs of Genital Herpes in the United States: Estimates From Insurance Claims.
Lifetime Medical Costs of Genital Herpes in the United States: Estimates From Insurance Claims.
复制标题
DOI：
10.1097/olq.0000000000001371
复制
发表时间：
2021-04-01
影响因子：
3.1
通讯作者：
中科院分区：
文献类型：
--
作者：
这项研究的目的是估计在美国每个生殖器疱疹病例的终身直接医疗费用。我们使用医疗索赔数据构建了一个队列，其中包括在2010年至2018年期间连续参加保险至少48个月的人。从这个队列中，我们确定了最初的生殖器疱疹诊断以及在最初诊断后的36个月内相关临床就诊和药物治疗的费用。根据36个月随访中观察到的治疗使用模式估计36个月以上的终生成本。生殖器疱疹终生直接医疗费用的现值估计为每个治疗病例972美元或每个感染165美元（2019年美元），不包括与预防或治疗新生儿疱疹相关的费用。首次诊断生殖器疱疹的临床就诊占一生费用的27%。与生殖器疱疹相关的后续临床访问和药物分别占终身成本的13%和60%。这项研究的结果可以为GH控制干预措施的成本效益分析提供信息，并有助于量化美国性传播感染的成本负担。根据医疗索赔数据，生殖器疱疹的平均终身直接医疗费用估计为972美元（每个治疗病例）和165美元（每个感染）。
The purpose of this study was to estimate the lifetime direct medical costs per incident case of genital herpes in the United States. We used medical claims data to construct a cohort of people continuously enrolled in insurance for at least 48 consecutive months between 2010 and 2018. From this cohort, we identified initial genital herpes diagnoses as well as the cost of related clinical visits and medication during the 36 months following an initial diagnosis. Lifetime costs beyond 36 months were estimated based on treatment use patterns observed in the 36 months of follow-up. The present value of lifetime direct medical costs of genital herpes was estimated to be $972 per treated case or $165 per infection (2019 dollars), not including costs associated with prevention or treatment of neonatal herpes. The clinical visit at which genital herpes was first diagnosed accounted for 27% of lifetime costs. Subsequent clinical visits and medications related to genital herpes accounted for an additional 13% and 60% of lifetime costs, respectively. The results from this study can inform cost-effectiveness analysis of GH control interventions as well as help quantify the cost burden of sexually transmitted infections in the United States. Based on medical claims data, the average lifetime direct medical cost of genital herpes was estimated to be $972 (per treated case) and $165 (per infection) in 2019 dollars.